The drug company CEO who jacked up the price of a life-saving pill to
$750 from $13.50 said he wishes he had raised the price even more.
Turing Pharmaceuticals chief Martin Shkreli is now facing new lower-priced competition and government scrutiny. But he said at a forum hosted by Forbes magazine Thursday that the outcry over his company’s list price for a Daraprim pill didn’t cause him any regrets.
“I probably would have raised prices higher, is probably what I should
have done.” said Shkreli, 32. “I could have raised it higher and made
more profits for our shareholders, which is my primary duty."
He continued, “No one wants to say it, no one's proud of it, but this
is a capitalist society, capitalist system and capitalist rules, and my
investors expect to me to maximize profits, not to minimize them, or go
half, or go 70%, but to go to 100% of the profit curve that we're all
taught in MBA class."
